Hans Moebius
Chief Tech/Sci/R&D Officer chez Exciva GmbH
Fortune : 250 661 $ au 31/03/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Mark Litton | M | 56 | 5 ans | |
| Kelly Romano | F | 62 | 4 ans | |
| Grant Pickering | M | 56 | 2 ans | |
| Joseph Edelman | M | 67 | 4 ans | |
| James Johnson | M | 67 | 4 ans | |
| Barbara Kosacz | F | 66 | 3 ans | |
| Mark Worthington | M | 58 | 3 ans | |
| Michael Panzara | M | 57 | 2 ans | |
| Robert Renninger | M | - | 4 ans | |
| Rachel Lenington | F | 51 | 3 ans | |
| Andrew Gengos | M | 59 | 1 ans | |
| François Conquet | M | - |
Exciva GmbH
 Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | - |
| Bespalov Anton | M | - |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Leen Kawas | M | 38 | 10 ans | |
| Tadataka Yamada | M | 77 | 2 ans | |
| Glenna Mileson | F | 66 | 8 ans | |
| George Bickerstaff | M | 68 | - | |
| Josh Pan | M | - | 7 ans | |
| Xue Hua | M | - | 7 ans | |
| Samantha Haeberlein | M | - |
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | - |
| Setsuko Hashimoto | M | 70 |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
| Helmut Kraft | M | 64 |
Ruprecht-Karls-Universität Heidelberg
| 5 ans |
| Norbert Steiner | M | 70 |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
| Bernd Eisele | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
| Roland Kaplan | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 ans |
| Klaus Dembowsky | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
| Bernhard R. M. Ehmer | M | 69 |
Ruprecht-Karls-Universität Heidelberg
| 6 ans |
| Utz-Hellmuth Felcht | M | 76 |
Technische Universität Kaiserslautern
| 3 ans |
| Peter Gruss | M | 74 |
Ruprecht-Karls-Universität Heidelberg
| 4 ans |
| Luis Miguel Cardozo Goytizolo | M | 73 |
Ruprecht-Karls-Universität Heidelberg
| 3 ans |
| Joachim Müller | M | 65 |
Ruprecht-Karls-Universität Heidelberg
| 4 ans |
| Richard Kayne | M | 79 | - | |
| Lawrence E. Chun | M | - | 7 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 20 | 60,61% |
| Allemagne | 13 | 39,39% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Hans Moebius
- Réseau Personnel
